Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients

British Journal of Cancer

Volumn 96, Issue 5, 2007, Pages 701-707

  Morris, M ^a   Platell, C ^a,b   Fritschi, L ^c   Iacopetta, B ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ST JOHN OF GOD HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

5 fluorouracil; Colon cancer; Health services; Mayo regime; Toxicity

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; AUSTRALIA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLON CANCER; CONFIDENCE INTERVAL; FEMALE; HEALTH CARE DELIVERY; HEALTH SERVICE; HUMAN; HUMAN TISSUE; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHYSIOLOGY; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HOSPITAL; RURAL AREA; SOCIOECONOMICS; SURGEON; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 33847719115     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603627     Document Type: Article

References (36)

1. Allegra C, Sargent DJ (2005) Adjuvant therapy for colon cancer - the pace quickens. N Engl J Med 352: 2746-2748
2. American Joint Committee on Cancer (2002) AJCC Cancer Staging Manual. 6th edn, pp 113-124. New York, NY: Springer
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351
4. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896-2903
5. Australian Bureau of Statistics (2001) Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA). Australia: ABS, Canberra
6. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617-3627
7. Chansky K, Benedetti J, Macdonald JS (2005) Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103: 1165-1171
8. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W (2006) Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98: 610-619
9. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3605-3616
10. Goyle S, Maraveyas A (2005) Chemotherapy for colorectal cancer. Dig Surg 22: 401-414
11. Iwashyna TJ, Lamont EB (2002) Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 20: 3992-3998
12. Jessup JM, Stewart A, Greene FL, Minsky BD (2005) Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294: 2703-2711
13. Jodrell DI, Stewart M, Aird R, Knowles G, Bowman A, Wall L, McLean C (2001) 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. Br J Cancer 84: 600-603
14. Katopodis O, Ross P, Norman AR, Oates J, Cunningham D (2004) Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital. Eur J Cancer 40: 2230-2236
15. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Watanabe G, Iacopetta B (2003) The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 9: 5860-5865
16. Meta-analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537-3541
17. Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10: 1171-1175
18. Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, Demard F (1994) Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12: 1291-1295
19. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358
20. Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL (2006) Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 24: 2368-2375
21. NIH consensus conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450
22. O'Connell MJ (2004) Current status of adjuvant therapy for colorectal cancer. Oncology 18: 751-755
23. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: 246-250
24. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664
25. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17: 2412-2418
26. Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, Weiss GR, Rivkin SE, Macdonald JS (2005) Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819-1825
27. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross PJ, Oates J (2003) Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88: 1859-1865
28. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzen F, Haller DG (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1, 864 patients. J Clin Oncol 25: 102-1099
29. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, Novotny PJ, Poon MA, O'Connell MJ, Loprinzi CL (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20: 1491-1498
30. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI (2002) Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136: 349-357
31. Tebbutt NC, Norman AR, Cunningham D, Allen M, Chau I, Oates J, Hill M (2000) Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. Br J Cancer 88: 1510-1515
32. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kroning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schuller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704
33. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B (2003) CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9: 2898-2903
34. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T, Hawkins NJ (2003) Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 21: 3729-3736
35. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, Defusco PA, Jochimsen P (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: 1879-1887
36. Zalcberg J, Kerr D, Seymour L, Palmer M (1998) Haematological and nonhaematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 34: 1871-1875